Tuesday, June 30, 2015

Net Element, Inc. (NETE) Active in its Pursuit to Become Premier Mobile Payments and Transactional Services Provider

It’s been a busy week for technology innovator Net Element as the company issued a shareholder update, inclusive of the company’s recent financing of at least $10.5 million to sustain further expansion initiatives, as well news that its pending acquisition target has signed a contract to process transactions for several international dating networks.

Net Element leverages its core technology innovations and operational business partners to provide mobile payments and value-added transactional services in emerging countries and in the United States. To this accord, the company is continuously seeking out growth opportunities.

In its recent news release, Net Element defined its primary goal for the second half of 2015 as integrating PayOnline’s value-added technologies with Net Element’s current U.S. offerings to solidify its foothold as a premier payments-as-a-service company with a centralized, omni-channel global platform.

Upon closing of the acquisition, Net Element will be able to sell its mobile payment services to PayOnline’s more than 10 million active consumers and thousands of merchants in the Russian Federation, Europe and Asia.

“The acquisition of PayOnline will be transformative for the Company not only as a profitable acquisition but for the cutting edge payments tools it provides such as its recently announced availability of an online transactional platform for iOS apps (iPhone and iPad),” Net Element said in the news release.

PayOnline’s recent three-year contract centers on a minimum processing commitment of $300 million in transactions for social networks AnastasiaDate, AmoLatina and AsianDate, among others. Net Element currently manages, operates and is in the process of integrating the PayOnline group of companies pending closing of Net Element’s acquisition of the company.

The acquisition will add to Net Element’s current portfolio of subsidiaries, which include TOT Group, Inc., a global mobile payments and transaction processing provider whose companies include Unified Payments, Aptito and TOT Money, and emphasizes Net Element’s ability to facilitate cross-border transactions through a single interface.

“This contract win demonstrates our ability to quickly derive value from strategic acquisitions and partnerships,” Net Element CEO Oleg Firer stated in the news release. “As we emerge from a period of financial and business restructuring, we plan to see more such value driving developments as we progress into our growth phase.”

The financial restructuring mentioned by Firer, along with other achievements and the pending acquisition of PayOnline, triggered a reiterated 12-month price target of $5.17 per share by SeeThruEquity.

“Net Element has achieved several important developments since our last update in March 2015. Most importantly, Net Element made substantial progress shedding cumbersome debt on its balance sheet and announced a new $24.5mn capital raise. While improving its financial position, the company also reported double-digit annual growth in both 1Q15 and fiscal 2014 results and announced several growth initiatives for 2015 and beyond. The company also announced that it had executed definitive documentation for the acquisition of PayOnline, a leader in online transaction processing services and payment technology with over 10mn active consumers and thousands of merchants in the Russian Federation, Europe and Asia. We are reiterating our 12 month price target on NETE of $5.17 per share,” stated SeeThruEquity CEO Ajay Tandon.

Net Element is quick on its feet in taking advantage of opportunities that add momentum to grow revenues, by attracting more merchants to its payments platform, contributing to its overarching mission to become a competitive leader in mobile payments and transactional services in target countries and the United States.

For more information visit www.netelementinc.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Bollente Companies, Inc. (BOLC) Looks to Capitalize on More Stringent Energy Regulations through Expansion of trutankless® Brand

Bollente Companies, Inc. (OTCQB: BOLC), through its trutankless® brand, is a manufacturer and distributor of innovative tankless water heaters in the United States. The company strives to create electric tankless water heaters that far surpass traditional tank water heaters in terms of energy efficiency, output, dependability and environmental sustainability while effectively overcoming the drawbacks of lesser tankless units.

In April, Bollente announced the release of a new line of water heaters geared toward budget-driven customers. These products, known as the Vero™ line, boast the same unrivaled water heating performance, durability and space savings of the trutankless flagship line at a fraction of the cost. Following the enactment of updates to the National Appliance Energy Conservation Act earlier this year, Bollente expects this new product line to provide an opportunity for sustainable market growth in the future.

“The new Department of Energy guidelines for water heaters are going to impact the majority of homes that currently use traditional tank water heaters,” Michael Stebbins, president of trutankless, stated in a news release. “Tanks will become larger and costlier to install, and homes requiring tank heaters that hold 55 or more gallons will have to upgrade to a heat pump for twice the cost, or go tankless. We are pleased to offer whole-home electric tankless solutions that already exceed the new energy factor guidelines.”

The company’s product offerings also include truCirc, a state-of-the-art water circulation pump designed to work seamlessly with its efficient water heaters. truCirc allows users to accurately track water usage throughout their homes and predict when hot water will be needed. By learning usage patterns, the device limits energy usage by keeping water hot only when it is likely to be needed. The product’s intuitive interface also allows homeowners to quickly and easily change delivery modes and zones to minimize wasted water.

“As a standalone product, truCirc provides tremendous energy and water savings for a household,” continued Stebbins. “When used in conjunction with a 99 percent energy-efficient trutankless unit, the end result is a complete water heating system with unrivaled efficiency, durability and long-term value to the homeowner.”

As the home construction industry continues to shift toward more environmentally-friendly solutions, Bollente is in a strong strategic position to record improved financial results. According to a report by McGraw Hill Construction, the overall green single-family housing market is expected to account for more than $80 billion in revenue by 2016, representing a 100 percent increase over the results of 2013. This continued market growth could provide Bollente with an opportunity to post strong results in the future.

Bollente’s proven product line provides the company with a platform to realize continued growth in the months to come. For prospective investors, this growth could translate into sustainable returns moving forward.

For more information, visit www.bollentecompanies.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Keryx Biopharmaceuticals, Inc. (KERX) Posts Strong Financial Results following Commercial Launch of Auryxia™

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that provide unique and meaningful advantages to patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™, in the United States for the treatment of elevated serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Keryx’s novel treatment is also being commercialized in Japan as Riona® for the treatment of patients with all stages of CKD by the company’s Japanese partner.

According to the National Kidney Foundation, approximately 26 million Americans currently suffer from kidney disease. Among those individuals, approximately 450,000 people are on dialysis treatments. For these people, maintaining serum phosphorus levels is imperative. An additional report by the National Kidney Foundation states that prolonged exposure to elevated phosphorus levels has been shown to cause increases in calcium-phosphate production, which is commonly associated with increased morbidity and, in many cases, mortality. This data highlights the immense market potential of Auryxia moving forward.

In the first quarter of 2015, Keryx leveraged the marketability of its groundbreaking product to record promising financial results. The company reported total revenue of approximately $1.2 million, including both U.S. product revenue and license revenue associated with sales of Riona in Japan. These figures are expected to rise in the future. In June, Keryx announced that Auryxia had been added to the Medicare Part D formularies of two national insurance providers, giving the company access to approximately 65 percent of people in the United States currently taking phosphate binders.

“The inclusion of Auryxia on the major insurance providers’ Part D formularies, which we expect will start processing claims in the third quarter, significantly expands unrestricted access to Auryxia for people on dialysis and their caregivers,” Greg Madison, chief executive officer of Keryx, stated in a news release. “Looking ahead, we are focused on continuing to raise awareness of Auryxia’s clinical profile among the prescribing community and ensuring that the vast majority of dialysis patients have access to this important medicine.”

In addition to plans of adding a team of field sales representatives in the months to come, the company’s short-term objectives include expanding the indication for Auryxia to include the treatment of iron deficiency anemia in patients with CKD. In September 2014, Keryx initiated a phase III study for this indication which is expected to be completed by the end of 2015.

For more information, visit www.keryx.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Monday, June 29, 2015

Feel Empowered to Make that Trade with TradePower.com

Purchasing stock confidently requires the right knowledge. As Francis Bacon, the father of the scientific method once stated, “Knowledge is power.”

In mankind’s agricultural past, ownership of land and property meant power. During the Industrial Revolution, ownership of factories and machinery became the basis of wealth and power. Now more than ever, in our globally integrated cybernetic information driven world, knowledge and information in and of itself has become the basis of wealth and power. Examples of those that are powerful due to our current knowledge based society include the wealth of Bill Gates to the influence of the large pharmaceutical companies of which both are based on intellectual property rights.

Control of information is something corporate elites always recognized as a way to consolidate and build wealth and power. In 1983, 90% of American media was owned by 50 companies. Right now, over 90% of the information diet of 313 million Americans is controlled by 6 corporations: News Corporation, Disney, Comcast, Viacom, Time Warner, and CBS. That is 90% of everything Americans see, hear, and consider important. As author Tom Clancy pointed out, those that control the information can control the people. Governments that are despotic have long recognized the importance of controlling the flow of information in a society. For example, China’s government controls its population in part by maintaining massive surveillance and a content control system over their population’s access to the Internet. As elites and governments recognize the importance of controlling knowledge and information, so should you be seeking to build on your sources of information.

Decisions do not happen in a vacuum. They are best made when the individual has sufficient information to weigh the possible consequences of various choices. Access to the right information gives decision-making power, builds your range of options from which to make choices, and is a key step toward empowerment and building wealth. Knowledge gives competence and the capacity to act, and sets one on a path of never ending and self-initiated growth.

One of TraderPower.com’s primary goals is to help investors make the right decisions and discover undervalued stocks poised for exceptional profits. For more information, visit www.TraderPower.com.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

ENGlobal Corporation (ENG) – Committed to Value

For three decades, ENGlobal has strived to become the preferred supplier of innovative engineering and automation solutions to a string of global clients. The company has aimed high with the intention of becoming the number one provider of novel automation integration services and select engineering, procurement, and construction management projects for the energy industry and other markets around the world.

In the time since its establishment in the 1980s, ENGlobal has become well-known. Today, the company is recognized as a specialty engineering services firm that focuses on serving a variety of markets from alternative energy, pulp and paper and government clients to the upstream, midstream and downstream sectors.

ENGlobal stakes its reputation on the consistent delivery of superior, value-added products and services that meet its commitment to quality. The company also closely follows the ISO-9001 standards that guide its industry to ensure it constantly delivers the best possible value for all stakeholders. Additionally, the team members at ENGlobal hold tightly to quality. It is one of six core values that govern the company’s operations, as seen below:

1.         Safety first
2.         Communication from the start
3.         Teamwork in everything
4.         Quality throughout
5.         Ethics without exception
6.         Total responsiveness

A Houston, Texas-based company, ENGlobal focuses on automation solutions and select engineering, procurement, and construction management projects. The company operates through these two business segments: automation and engineering. The automation segment offers integrated services linked to designing, fabricating and implementing advanced automation, distributed control, instrumentation and process analytical systems – and its solutions fall under two categories: integration and engineering. The EPCM segment provides consulting services for the development, management and execution of projects requiring professional engineering, construction management, and related support services.

For more information, visit www.englobal.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Net Element, Inc. (NETE) Reports Pending Acquisition’s New 3-Year Contract with Dating Networks

Earlier this morning, Net Element announced that PayOnline signed a new 3-year contract to process transactions for certain international dating networks, including AnastasiaDate, AmoLatina and AsianDate. Collectively, these networks receive more than 150 million unique visits annually and have more than 4 million registered users that spend more than 360 million hours on the sites per year.

Net Element currently manages, operates and is in the process of integrating the PayOnline group of companies pending closing of its previously announced acquisition initiative.

The contract with the majority owner of the dating networks, Social Discovery Ventures (“SDV”), is expected to achieve minimum net revenues to Net Element in the amount of $1.2 million over 3 years and a minimum transaction processing commitment of $300 million.

The contract underscores Net Element’s advantage as a global payments-as-a-service platform that facilitates cross-border transactions yet on-boards through a single interface.

SDV’s dating networks will use PayOnline’s state-of-the-art global online payments gateway and fraud-management tools to manage its international online transaction processing.

“The millions of international users on our premium dating networks require a reliable service able to process high volume, cross-border transactions using all forms of payments,” stated Anthony Volpe, Social Discovery Ventures chief marketing officer. “We selected Net Element because they met that need.”

“This contract win demonstrates our ability to quickly derive value from strategic acquisitions and partnerships,” added Oleg Firer, Net Element CEO. “As we emerge from a period of financial and business restructuring, we plan to see more such value driving developments as we progress into our growth phase.”

For more information on Net Element, visit www.netelement.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Callidus Software, Inc. (CALD) Leveraging Proprietary Lead-to-Money Suite to Record Improved Financial Results

Callidus Software, Inc. (NASDAQ: CALD), doing business as CallidusCloud®, is the global leader in cloud-based sales, marketing, learning and customer experience solutions. The company’s proprietary suite of business offerings enables customers to identify leads, ensure proper distribution, enable sales forces, automate price quoting and streamline sales compensation in order to secure larger deals in less time. The company’s current customer base, which includes over 3,900 leading organizations in a variety of industries, relies on Callidus to optimize the lead-to-money process, opening the door for more revenue on an accelerated schedule.

By automating key portions of the marketing and sales processes, Callidus addresses the historical divide between the two vital business components. This groundbreaking approach to increased market share has helped the company achieve a host of recognition from the industry. In 2014, Callidus was awarded the ‘Cloud Computing Product of the Year Award’ by Cloud Computing magazine, as well as named ‘Best New Product – Financial Services’ at the International Business Awards℠, for its lead-to-money suite.

In the first quarter of 2015, Callidus built on this industry recognition by posting impressive financial results. Benefitting from the continued success of its product suite, the company recorded total revenue of $39.7 million, which was a substantial 28 percent year-over-year improvement, as well as a 37 percent year-over-year increase in SaaS revenue.

“I was pleased with our focus on execution in [the first quarter],” Leslie Stretch, president and chief executive officer of Callidus, stated in a news release. “In a busy quarter when we moved our headquarters and conducted a successful secondary offering we achieved record revenues and record recurring revenues. We beat both our cloud revenue growth percentage and total revenue guidance.”

Callidus is in a strong position to continue expanding upon its recent financial performance in the future. According to a report by MarketsandMarkets, the current value of the sales performance management (SPM) software market is estimated to be approximately $2.48 billion, and the sector is expected to grow to $5.62 billion by 2020. As businesses around the globe continue to shift from spreadsheets to the cloud, the company’s groundbreaking lead-to-money suite should present Callidus with an opportunity to promote strong market growth.

“The growth in the SPM market is driven by customers… who are looking to advance beyond traditional ineffective sales methods encumbered by spreadsheets,” Eric Brown, Callidus’s senior vice president of sales, stated. “The benefits of a modern, customer-centric selling solution are huge.”

For prospective shareholders, the near limitless market potential of the company’s software suite makes Callidus an intriguing investment opportunity moving forward.

For more information, visit www.calliduscloud.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Heron Therapeutics, Inc. (HRTX) Addressing Unmet Medical Needs through Continued Development of Leading Drug Candidates

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology company focused on the development and commercialization of best-in-class pharmaceutical products that address major unmet medical needs. The company’s leading drug candidate, SUSTOL®, is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV), which affects approximately 75 percent of patients undergoing cancer treatment.

SUSTOL improves upon the current treatment options for CINV by utilizing Heron’s proprietary drug delivery platform, Biochronomer®. The company’s groundbreaking delivery technologies allow for sustained levels of drugs in systemic circulation, providing prolonged efficacy in a variety of potential applications. In clinical studies, Heron has demonstrated these benefits, with SUSTOL maintaining therapeutic drug levels for up to five days with a single subcutaneous injection.

In recent months, the company has taken significant steps toward the eventual commercialization of SUSTOL. In May, Heron announced the top-line results from its 900 patient phase III clinical study of the product candidate. According to these results, SUSTOL provided significantly higher rates of complete response than the test’s three-drug standard of care comparator group, demonstrating the overall efficacy and market potential of the candidate.

“[T]he results… further demonstrate the potential for SUSTOL to be the foundation of the new standard-of-care injectable anti-emetic regimen,” Barry D. Quart, chief executive officer of Heron, stated in a news release. “[W]e are planning for the commercial launch of SUSTOL, pending FDA approval.”

In addition to its progress with SUSTOL, Heron has also taken significant steps in the development of its second drug candidate, HTX-011, in recent weeks. Earlier this month, the company announced the initiation of a phase II clinical trial on the candidate for the prevention of post-operative pain. By effectively assisting patients in managing pain with a reduction in the use of opioids, as compared to the current standard of care, HTX-011 could provide Heron with an additional platform to realize continued growth in the future.

“We believe that HTX-011 has the potential to meet our core goal of developing best-in-class medicines with the potential to significantly improve the lives of patients,” continued Quart.

For prospective investors, Heron’s rapid progress toward the commercialization of its two leading drug candidates could provide a platform to realize substantial returns in the years to come.

For more information, visit www.herontx.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Anthera Pharmaceuticals, Inc. (ANTH) Progressing toward Commercialization of Advanced Product Pipeline

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of products to treat serious and life-threatening diseases. The company’s product pipeline includes two phase III product candidates. The first, Blisibimod, is currently being studied for the treatment of lupus, a chronic disease that causes a patient’s immune system to attack his or her own tissues and organs. The second, Sollpura™, is currently being studied as a novel pancreatic enzyme replacement therapy for the treatment of cystic fibrosis and related diseases.

In recent months, Anthera made major strides toward the eventual commercialization of these two groundbreaking drug candidates. In March, the company secured a research award of up to $3 million from Cystic Fibrosis Foundation Therapeutics, Inc. to support the manufacturing and clinical development of Sollpura.

“Support from Cystic Fibrosis Foundation Therapeutics speaks to the importance of developing [Sollpura] and the organization’s extensive clinical trials network will be indispensable as we advance this therapy,” Paul F. Truex, president and chief executive officer of Anthera, stated in a news release.

Earlier this month, the company made significant progress in the development of Blisibimod by reaching the target enrollment goal for its CHABLIS-SC1 phase III clinical trial. The results from this study, which are expected to be available in the second half of 2016, are anticipated to support the eventual market approval of Blisibimod for the treatment of lupus.

“Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” stated Dr. Colin Hislop, chief medical officer of Anthera. “The accelerated pace speaks to the importance of patient identification and selection in lupus treatment.”

When commercialized, these two products could provide Anthera with a strong platform to realize considerable growth within the biopharmaceutical industry. According to the Lupus Foundation of America, an estimated 1.5 million Americans, and at least five million people worldwide, suffer from some form of Lupus. Likewise, according to the Cystic Fibrosis Foundation, an estimated 30,000 Americans, and approximately 70,000 people worldwide, suffer from cystic fibrosis.

For prospective investors, Anthera’s continued progress toward commercialization of its two unique drug candidates makes the company an intriguing investment opportunity in the months to come.

For more information, visit www.anthera.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Synergy Resources Corp. (SYRG) Building Shareholder Value through Expanding Presence in Denver-Julesburg Basin

Synergy Resources Corp. is a domestic oil and natural gas exploration and production company operating in the Wattenberg Field of the Denver-Julesburg Basin in northeast Colorado. The company operates 308 wells throughout the region, in addition to having an ownership interest in nearly 300 net producing wells. Through these projects, Synergy has access to an estimated 40.3 million barrels of oil equivalent, according to a February report by independent oil and gas consulting firm Ryder Scott Company.

The Denver-Julesburg Basin has established itself as one of the most important producing areas in the country by consistently generating oil and gas since its discovery in 1901. The total value of past production from the region, if calculated in modern prices, would exceed $150 billion. For Synergy, the basin’s high level of predictability and high drilling success rate could provide the company with an opportunity to achieve rapid return on investment in the future.

During its fiscal second quarter of 2015, Synergy leveraged its position within the Wattenberg field to dramatically increase production. In addition to increasing year-over-year revenue by three percent, the company recorded a 98 percent year-over-year increase in overall production. Primarily, this spike was a result of Synergy’s December acquisition of a 5,040 acre leasehold in the Wattenberg Field, which provided access to 73 operating vertical wells, as well as non-operated working interests in 17 horizontal wells.

“Our growth in proved reserves is a result of the success of our operated horizontal drilling program, the performance of the horizontal wells in the Wattenberg Field, and proved reserves added as a result of our acquisition we completed in December,” William E. Scaff, co-chief executive officer of Synergy, stated in a news release.

In May, Synergy continued to expand its presence in the Denver-Julesburg Basin when it reached an agreement with its non-operating partner to purchase the remaining 35 percent working interest in the Greenhorn prospect, which is located in the northeast extension area of the basin.

“Over the past twelve months we have been pursuing a higher working interest in all of our operated assets both in the core of the Wattenberg Field and in the extension area,” Scaff continued. “This acquisition… is consistent with that objective.”

Despite a sharp decrease in commodity prices that’s persisted throughout the first six months of 2015, Synergy’s recent performance is a promising indication for prospective investors moving forward. Look for the company to leverage its established position within the Greater Wattenberg Field with the goal of encouraging sustainable returns in the years to come.

For more information, visit www.syrginfo.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Friday, June 26, 2015

Net Element (NETE) Executing on Mission and Vision for Growth in Mobile Payment Market

Talk among industry researchers on the street indicate that the U.S. mobile payment market will eclipse $90 billion spent in 2017. This number characterizes a resounding 48 percent compounded annual growth rate over the $12.8 billion spent in 2012. For those whose endeavors involve building shareholder value, the mobile payment market is viewed as very fertile ground.

Corroborating data from Juniper Research indicates as much as $110 billion in transactions are anticipated across the U.S., Western Europe and Canadian markets for the same period. ABI Research is predicting approximately $190 billion for 2017 for global NFC-based mobile payments made in October 2014.

Net Element (NASDAQ: NETE), a global payments-as-a-service, technology provider with an integrated mobile and transactional services platform, has assembled what many have referred to as an impressive collection of building blocks that enable the company to catch this emerging technology wave and create the kind of value the investor intended to receive from the get-go. The company’s wholly owned subsidiary, TOT Group, operates Unified Payments, a U.S. focused transaction processing and value-add brand; Aptito, a cloud-based point of sale payments platform; and TOT Money, a mobile payments service provider previously ranked in the Top 3 mobile payments providers by Beeline, a leading Russian telecommunications company.

Characterized as a significant building block for growth, NETE is fully engaged in definitive agreements with a qualified institutional buyer and certain institutional accredited investors for financing transactions. The company is now working with $10.5 million as well as the potential for future funding of up to $14 million to further advance the company business model and mission.

For more information on the company, visit www.netelement.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Continental Stock Transfer & Trust – Fifty Years of Excellence in Service

Transfer agents may perform the same basic functions but the team at Continental Stock Transfer & Trust knows that being the agent of choice requires more. As only major transfer agent specializing in small to midsize emerging and growth companies, Continental plays the critical role of record keeper and shareholder information depository with stability, agility and the knowledge that a company’s needs, size and service expectations drive its choice of transfer agent.

At Continental, there is nothing “usual” about how business is conducted. The company goes above and beyond to cater to its clients and their shareholders. It supports unique needs and expectations — and goes the extra mile to execute exactly what it’s needed, when it’s needed, so that its clients can proceed with business.

With round-the-clock access to its high-level experts, Continental offers what few, if any, mega transfer agents offer: a responsive and truly personalized business solution that is backed by five decades of unmatched industry experience.

In 1964, Continental Stock Transfer & Trust was founded on the premise that the company would support small and midsize companies with comprehensive, uniquely-tailored business solutions and superior client responsiveness. In the years since, the company has never wavered in pursuit of this vision. As in its beginning, Continental remains an independent, privately-held, family-owned corporation – and it has no intention of changing. It is fully committed to partnering with its clients for the long term.

A solid base and staff of experienced professionals fuel Continental’s operations, allowing the company to respond swiftly and deftly to its clients and their shareholders. They also enable the company to develop and implement its suite of services flawlessly. This type of consistent, top-notch delivery is what makes Continental a major presence in the industry.

For more information, visit www.continentalstock.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html


Paratek Pharmaceuticals, Inc. (PRTK) Addressing Antibiotic Resistance through Development of New Class of Antibiotics

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s leading product candidate, omadacycline, is the first in a new class of antibiotics derived from tetracyclines for use as a first-line monotherapy to treat serious bacterial infections when antibiotic resistance is a cause of concern.

In recent weeks, Paratek has continued to progress with the development of omadacycline. Earlier this month, the company initiated a phase III clinical trial of the drug candidate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). This study is meant to assess the efficacy and safety of omadacycline in treating ABSSSI, particularly as compared with current treatment option linezolid. The company’s second phase III trial on the drug candidate, which will begin enrolling patients later this year, will study its effectiveness in treating community-acquired bacterial pneumonia (CABP).

“The initiation of our registration trial for ABSSSI represents an important milestone for Paratek as a company,” Michael Bigham, chairman and chief executive officer of Paratek, stated in a news release. “We believe that omadacycline has the potential to become an important empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, urinary tract infections and other bacterial infections when resistance is of concern.”

Upon commercialization, the potential market for Paratek’s novel antibiotic treatment is immense. According to a 2013 report by the Centers for Disease Control and Prevention, at least two million people in the United States become infected with bacteria that are resistant to conventional antibiotic treatment options each year, and an estimated 23,000 people die as a result of these infections.

In the first quarter of 2015, Paratek positioned itself to move forward with its omadacycline trials by securing approximately $71 million in funding through a common stock offering. With financing complete, the company will look to accelerate its existing clinical development plans, as well as adding a third potential indication in urinary tract infections (UTI), in the months to come. Based on current assumptions, Paratek’s cash and cash equivalents are expected to fund operations through mid-2017, which is expected to coincide with the availability of top-line data from the company’s CABP trial.

For prospective shareholders, the vast market potential of omadacycline and the current financial standing of Paratek combine to make the company an intriguing investment opportunity moving forward. As Paratek continues to make strides toward the commercialization of its innovative drug candidate, look for the company to clear the path for sustainable returns in the years to come.

For more information, visit www.paratekpharm.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Organovo Holdings, Inc. (ONVO) Making a Splash in Biopharmaceutical Industry with Innovative 3D Bioprinting Technology

Organovo Holdings, Inc. (NYSE MKT: ONVO) is an early commercial stage company focusing on the development and commercialization of functional human tissues for use in drug discovery and medical research. Utilizing its proprietary three-dimensional bioprinting technology, the company enables reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. Organovo’s exVive3D™ product portfolio includes a recently launched 3D human liver tissue for use in toxicology and preclinical drug testing. The company plans to expand upon its existing product portfolio in the latter half of 2016 through the launch of its exVive3D human kidney tissue.

Since launching its 3D human liver tissue on April 1, 2014, the company has made significant strides toward increasing its market share within the $50 billion research and development sector of the pharmaceutical industry. Earlier this month, Organovo reported that it had already recording total contract bookings for its innovative product amounting to approximately $1.94 million, including $0.29 million in existing revenue. Among these orders, the company secured partnerships with top 25 global pharmaceutical companies, as well as additional public pharmaceutical companies of all sizes in the United States, Europe and Asia.

“Response to the exVive3D human liver tissue has been strong, and in line with our expectations,” Keith Murphy, chief executive officer of Organovo, stated in a news release. “We continue to expect this tissue to grow into the tens of millions in annual revenue, and that it has $100M+ revenue potential.”

For Organovo, fiscal year 2015 was filled with milestones that should provide the company with a strong platform to realize sustainable returns moving forward. The release of the exVive3D human liver tissue set the stage for a host of industry recognition – including being named among the ‘Top 10 Innovations of 2014’ by The Scientist magazine and ‘The World’s Top 10 Most Innovative Companies of 2015’ by Fast Company magazine. Additionally, Organovo diversified its market potential through a partnership with L’Oreal USA to develop 3D printed skin tissues for product evaluation, marking the company’s first foray into the beauty industry.

The company’s current momentum following the successful release of its initial product could be a promising indication of Organovo’s future growth potential. For prospective shareholders, the recent commercialization of its exVive3D human liver tissue, as well as the continued development of its human kidney tissue product, makes Organovo an exciting investment opportunity to put on radar.

For more information, visit www.organovo.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Thursday, June 25, 2015

Cytori Therapeutics, Inc. (CYTX) Establishing Early Presence in Emerging Field of Regenerative Medicine

Cytori Therapeutics, Inc. is a biotechnology company developing autologous cell therapies from adipose connective tissue designed to treat a variety of medical conditions. Since 2001, the company has leveraged its exploration of the massive treatment potential of adult adipose-derived stem and regenerative cells to position itself as a global leader in the emerging field of regenerative medicine. By utilizing a patient’s own adipose tissue, Cytori eliminates the necessity for offsite cell growth operations while effectively minimizing common transplant risks, including autoimmune rejection.

The company’s current cell therapy pipeline includes three drug candidates in six unique indications across two countries and the European Union. Cytori’s leading candidate, ECCS-50, is currently approved in the United States and Europe to begin a phase III clinical trial for the treatment of scleroderma hand dysfunction.

According to the National Institute of Health, scleroderma is a group of diseases that affect connective tissue in the body, potentially causing swelling or pain in the muscles and joints. Despite affecting as many as 100,000 people in the United States, there is currently no drug that has been clearly proven to stop, or reverse, the disease’s key symptoms. For Cytori, this unmet need should clear the way for favorable results upon the eventual commercialization of ECCS-50.

From a financial standpoint, Cytori took major steps in the first quarter of 2015 toward continued development and testing of its promising product pipeline. The company’s operating cash burn was reduced by over 44 percent in the period and overall contract revenue rose by 350 percent, as compared to the first quarter of 2014, providing prospective investors with a preview of the Cytori’s growth potential moving forward.

“We accomplished the key objectives we hoped to achieve over the past four quarters and are off to a good start in 2015,” Dr. Marc H. Hendrick, president and chief executive officer of Cytori, stated in a news release. “Now the lion’s share of our corporate focus and energy will go into trial enrollment and strategically managing our clinical pipeline.”

In June, the company made progress toward this objective through the completion of enrollment for its impending phase IIb clinical trial, which will study the safety, feasibility and dosing intraarticular administration of Cytori’s ECCO-50 cellular therapeutic in patients with knee osteoarthritis. Look for the company to build on this progress in the months to come as it prepares for its pivotal phase III trial of ECCS-50.

For more information, visit www.cytori.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Wednesday, June 24, 2015

ENGlobal Corp. (ENG) Trusted Reputation, Diverse Capabilities in Automation & EPCM Maintain Momentum as Potential Crude Supply Shortfall Looms

There was a solid pop in oil futures Tuesday, June 23, with August crude holding above $61.00 a barrel as the API and EIA supply reports this week are expected to show tightening in domestic supply figures. Platts polling data indicates an anticipated reduction of 2.3 million barrels amid heightened tension between the U.S. and Russia, the world’s number two oil producer, with U.S. SecDef Carter having announced a firm reinforcement of Europe and massively increased logistical support to NATO’s rapid reaction force, in order to face threats from the east or from extremists in the increasingly deteriorating Middle East. Significant reduction in CAPEX over the last several months by U.S. E&Ps of around 25 percent or higher, extending through Q1 this year, has organized a groundswell in oil futures, which are forecast to continue rising over the longer-term despite a stronger dollar.

Also, the continued moves by China and Russia to sign landmark energy deals show a continued dedollarization of crude that threatens to unseat the petrodollar. Massive potential investment in Rosneft’s (OTC: RNFTF) huge new Vankor field in eastern Siberia by China and India is clearly in the cards, with delegations from both countries having made recent visits to Vankor and statements from Russia’s Deputy Prime Minister indicating that the country has cleared a psychological barrier that previously prevented Russia from giving China a measure of control over its hydrocarbon reserves. The entire 440k BOPD output from Vankor is already being shipped out to feed Asia via the ESPO pipeline, with the vast majority of output ending up in northeastern China.

In this near-term environment of reduced upstream activity among domestic E&P operators, the larger sector players stand to do best, because they have the kind of geographical and infrastructural diversity, economies of scale, widespread exposure and overall size needed to survive and thrive. The impending Halliburton (NYSE:HAL)-Baker Hughes (NYSE: BHI) merger and other such consolidation in the sector is a clear indicator of the underlying market dynamics here and it is also a key expression of the sector finding its footing. In fact, Denver-based Markwest Energy Partners (NYSE: MWE), which derives much of its operational cash flow from fees, has established agreements with more than 160 producers, roughly 4.7k miles of pipelines and around six billion cubic feet per day in natural gas processing capacity, is actually firmly focused on growth. With as much as $1.9 billion in CAPEX lined up for this year alone, across 20 major projects that are currently under construction on over nine million acres throughout the country’s top producing basins in Texas, Oklahoma and the northeast (emphasis on the Marcellus shale), Markwest is even on track to do four major plant expansions in Ohio.

For a company like energy-related EPCM (engineering, procurement and construction management) and automation specialists ENGlobal (NASDAQ: ENG), which is one of the most well-positioned and top-ranked providers of full spectrum services in the field today, the aforementioned market dynamics are good news. Because in order to thrive in this arena, especially under the current conditions, a reputation for excellence and the ability to deliver on time and within budget is paramount when it comes to attracting business from the biggest players. A long, established track record of success with top sector players will serve ENGlobal well in helping to further court the business of those energy sector juggernauts which are most able to withstand the temporary slowdown in capital expenditures, as well as the smaller contrarians who are shrewdly doubling down into the sector nadir.

Even with the downturn in energy commodity prices having impacted ENGlobal’s overall upstream related orders in Q1 this year, the company has maintained profitability, with a strong working capital position of over $24 million, and zero borrowings under their current credit facility. Automation operating profit margin outpaced the company’s EPCM division during the first quarter of 2015, posting a still healthy 13.9 percent, whereas engineering and construction profit margins were on par with Q1 2014. This is thanks in large part to the company’s vast expertise in both automation integration and automation engineering. ENGblobal’s ability to deliver a full range of integrated process, power and control solutions, handling everything in-house from the fabrication, assembly and programming, to documentation and system testing, has helped win the company a reputation as a rock-solid reliable supplier of integration solutions.

By being able to provide integration support ranging from analytical units like continuous monitoring, analyzer maintenance and data acquisition systems, to custom industrial HVAC (heating, ventilating, air-conditioning) systems and hydrocarbon moving infrastructure, like pipelines and rail/truck or sea terminals, ENGlobal has firmly cemented itself in the minds of some of the industry’s biggest companies as a provider who can handle anything that is thrown at it. Other automation integration systems provided by the company include a vast array of power solutions, like switchgear shelters and micro-turbine power islands, as well as complex control systems like master panels, burner management systems, SCADA (supervisory control and data acquisition using coded signals) controls, and fire/gas protection systems.

The company actually specializes in the kind of robust modular enclosures needed for everything from general operator shelters and control rooms, to heat and blast resistant cabinets used in some of the energy industry’s most dangerous environments, such as refinery process units and on drilling rigs. Far more than just a successful integrator, ENGlobal can design, fabricate, manufacture and fully test the kinds of highly modular, fully integrated control cabins that are ideal for today’s most advanced automated drilling rigs. A highly experienced automation staff with years under their belts, doing everything from DCS (distributed control system) migrations, plant re-instrumentations and complete expansions, to customized electrical, control system and instrument initializations, stands at the ready to help the company’s clients.

By providing everything from commissioning and process control start-up support, to power distribution and generation, as well as loop check, complete analytical verification and even EPA-regulated system automation services, ENGlobal is able to stay profitable and attract new business, even when times are tough in the industry, maintaining profitability on the strength of reputation and a diversity of offerings. It is this capacity to deliver automation and control system services that span the gamut, covering almost any task imaginable, from conception through to execution, which will continue to make the company attractive amid further industry consolidation as we potentially head towards a more lively sector rebound sometime in mid to late 2016.

Research and investing information provider Cowen & Co analysts are projecting small to mid-cap E&P’s are in for some rocky terrain next year, with a $16 billion shortfall between cash flow projections and spending estimates, requiring some $8.6 billion in order to meet production growth projections for 2016. This reality will continue to fuel M&A activity within the sector and for companies like ENGlobal, an ability to court the biggest players will be a deciding factor, whether the work is at home or abroad.

Significant domestic tightness in crude supply over the next two months into July and August, driven by increased drawdowns like those we have seen over the preceding seven weeks, but clocking in at as much as eight million barrels per week, could push crude to over $70 a barrel according to recent analysis from OptionSellers. As Americans increasingly hit the roads for the peak of driving season, associated draws in secondary products like gasoline should also rise, putting even more wind in the energy market’s sails. This price activity could seriously pan out longer term as the true impact of the recent, dramatic reduction in upstream activity like new well starts becomes more and more obvious. New well starts were off by 105 percent compared to last year in May, down to 1,761 from 3,625 according to RigData. A trend tracked by permits, which were also off substantially from the same period last year, showing a 75 percent reduction from 2014, to around only 898 in May. People keep talking about a supply glut, but unless upstream activity picks back up to levels seen before the crude price crashed in late 2014, supplies could dry up quickly and ignite a bull market in E&P capital expenditures, as we scramble to meet demand without having to return to a paradigm dominated by OPEC exports.

Dig deeper into ENGlobal by visiting www.englobal.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Net Element, Inc. (NETE) Highlights Financial Progress in Recent Business Update

Net Element, Inc. (NASDAQ: NETE) issued a response to shareholder inquiries on Tuesday, addressing concerns regarding the company’s recent decline in share prices and the resulting non-compliance notice received from NASDAQ. In particular, the company highlighted its primary goals for the second half of 2015 following the successful negotiation of up to $24.5 million in financing in recent months.

In May, Net Element executed definitive documentation to acquire PayOnline, a leader in online transaction processing services and payment technology. Management suggests that this acquisition will be transformative for the company moving forward as both a profitable subsidiary and an established platform for growth in the online payments industry. Earlier this month, the company leveraged this platform by launching its online payments processing business in Kazakhstan through a contract with the country’s largest online events ticketing website and second largest online merchant.

“Net Element’s facilitation of this banking relationship with its pending acquisition PayOnline is an example of how we intend to grow in emerging markets, where we can nimbly deliver those services best suited for a given market,” Oleg Firer, chief executive officer of Net Element, stated in a news release. “We expect this agreement to accelerate our growth in the region.”

The company has made similar strides toward sustainable growth in the U.S. market through the launch of three new programs to provide financing solutions and sales incentives to sales partners in order to help accelerate business development. With this new recruitment program in place, Net Element will look to aggressively expand its domestic footprint by facilitating the business success of its partners.

This progress, in addition to persistent growth in the Russian mobile payments market, has allowed the company to improve its financial results in recent months. In the first quarter of 2015, Net Element reduced its year-over-year net loss by more than 63 percent through its dedication to the elimination of debt over the past two years. These savings, along with the company’s newly secured growth capital, should allow Net Element to continue implementing its strategic growth plans.

For more information, visit www.netelement.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Apricus Biosciences, Inc. (APRI) Expanding Presence in Biopharmaceutical Industry through Commercialization of Vitaros®

Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. The company’s lead product, Vitaros®, is approved in Europe and Canada for the treatment of erectile dysfunction and is currently being commercialized in several European countries. In addition, Apricus’s product pipeline includes Fispemifene for the treatment of secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms in men and RayVa™ for the treatment of Raynaud’s phenomenon.

Through the commercialization of Vitaros, Apricus is establishing a foothold in one of the biopharmaceutical industry’s most consistently performing sectors. According to Medtech Insight, erectile dysfunction affects an estimated 150 million men globally, and that total is expected to double by 2030. As a result, the market for these drugs has grown to over $4.2 billion. For Apricus, this could provide a significant opportunity to grow within the industry as it continues to expand the commercialization of Vitaros.

Vitaros is a locally-applied topical cream, allowing the product to differentiate itself from the phosphodiesterase inhibitors currently on the market, which are distributed in tablet form. As a topical cream, Vitaros has been shown to provide rapid onset benefits with significant efficacy and a favorable safety profile.

In May, the company took a major step toward continued growth through the launch of its novel treatment in France. This launch, in addition to its recent launch in Spain, brings the total number of European markets in which Vitaros is now commercially available to six. In the first quarter of 2015, Apricus prepared to build on these efforts by raising $11 million in cash from financing activities, as well as establishing revenue of $475,000. In the coming months, Apricus will look to grow revenue in penetrated markets while continuing to expand into other European countries.

“[W]e continue to be pleased with our commercial partners’ efforts to establish Vitaros as the erectile dysfunction treatment of choice in Europe,” Richard Pascoe, chief executive officer of Apricus, stated in a news release. “[W]e regard Vitaros as a strategic asset with the potential to generate meaningful long-term revenue for the company.”

For prospective investors, the continued expansion of Vitaros throughout Europe is a promising step toward sustainable returns moving forward.

For more information, visit www.apricusbio.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Tuesday, June 23, 2015

DexCom, Inc. (DXCM) Providing a More Convenient Way to Monitor Glucose Levels

DexCom, Inc. (NASDAQ: DXCM) develops and markets continuous glucose monitoring (CGM) products and tools to help adults and pediatric patients better manage their diabetes. CGM is an FDA-approved technology that provides real-time readings throughout the day and night, allowing for more accurate tracking of glucose levels with as many as 288 readings per day. Utilizing a small sensor just under the skin, the company’s device wirelessly transmits data to an innovative receiver that vividly displays glucose trends and alerts patients when they’re outside of the acceptable range. DexCom currently offers its groundbreaking monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in hospitals.

The potential market for this technology is extensive. According to a report by the Centers for Disease Control and Prevention, more than 29 million Americans are currently living with diabetes, and it is also the seventh leading cause of death in the United States. In 2012, diabetes and its complications accounted for approximately $245 billion in total medical costs and lost wages.

In the first quarter of 2015, DexCom leveraged this market potential to realize improved financial results. The company’s total revenue for the period was $72.8 million, which was a 55 percent year-over-year increase. Similarly, DexCom realized a 56 percent boost in total gross profit, recording $46.5 million for the quarter.

The company’s dedication to innovation has placed it in a strong strategic position to continue expanding its market presence in the coming months. In April, DexCom introduced a revolutionary app that combined its CGM technology with the convenience of the Apple Watch™. The DexCom G4® PLATINUM Continuous Glucose Monitor System with Share™ is an FDA-approved solution that allows users to discreetly review life-saving glucose data directly from their wrist or iPhone. Earlier this month, the company expanded on this innovation by releasing an Android-compatible version of this technology.

“DexCom aims for optimal convenience and accessibility by providing our patients and their loved ones with access to the most current technology to better manage their diabetes,” Kevin Sayer, chief executive officer of DexCom, stated in a news release.

For prospective investors, the company’s established position within the diabetes management industry should provide a formidable platform to realize improved returns in the years to come. DexCom’s continued commitment to innovation and market growth could open the door for sustainable returns in the future, making the company an intriguing investment opportunity moving forward.

For more information, visit www.dexcom.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

MissionSMR Leverages Social Technology to Provide Clients with a Powerful, Successful and Radical Outreach Platform

The applications for social technology in the corporate world are moving at warp speed. Once a means of entertainment, e-mail access and online shopping, social technology has become so entrenched within global businesses, that it is unarguably one of the most powerful and yet largely untapped business tools on the planet.

In a McKinsey & Company study of 4,200 companies around the world, 70% report that they currently use social technology in some form or fashion; and 90% of those companies said they were seeing some degree of business benefit. However, only 3% of companies were fully networked to achieve substantial benefits from these technologies.

Recognizing the deep, untapped potential for social technology to improve communications and collaboration within and across enterprises is one thing. Executing a plan to actually participate in and take advantage of the billowing market is quite another.

Social technologies serve as a platform for the key fundamentals of a progressive and thriving outreach strategy. At MissionSMR we help our clients leverage social technology in regards to:

•           Operations and distribution
•           Investor Relations
•           Marketing and Sales
•           Customer Service
•           Business Support

As a valued MissionSMR client, your company, initiatives and challenges are taken seriously. The team of professionals is committed to:

•           Delivering news and key investment highlights to targeted audiences
•           Establishing presence on prominent investor-oriented sites
•           Generating buzz with wide distribution and consistent communication
•           Optimizing and refining social networking strategy
•           Adding power and reach to existing investor relations programs
•           Strategic execution and specialized expertise
•           Proven results and prompt service

MissionSMR leverages the incredible dynamics of social media that set it apart as a leading and preferred means of communication among businesses, investors and consumers. Peeling back layer by layer, the team gets to the core of how your company can fully maximize social media and execute the most effective plan. This is more than a Facebook or Twitter account – this is using a well-established network and fine-tuned strategies to help you get noticed and stay on top.

To learn more, visit www.MissionSMR.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Net Element (NETE) Poised for Solid Growth in Soaring Mobile Payment Market

Not long ago, the thought of using your smartphone to pay for merchandise at retail shops was considered wishful thinking. It was fun to talk about but those in conversation knew the technology needed to make it happen was not yet available.

Today, the ‘what if’ conversation, according to payments industry experts, has become an undeniable reality.

According to research firm, Forrester, mobile payments in the United States are trending from $50 billion today to $142 billion in 2019. In a recent study, Forrester spoke to a dozen payments industry companies, including Visa, PayPal and Verifone and noted that the shift to mobile commerce was growing quickly.

PayPal, Google and AT&T have tried for years to create their concept of a mobile wallet, but progress has been slow. Forrester’s research shows that the market has matured since 2010, and sees the next four to five years as the period where mobile payments break into the economy’s mainstream.

Denée Carrington, a Forrester analyst commented, “It’s not just that we have smartphones. It’s that we’re increasingly dependent or rely on or expect them to deliver more.” Further, Ms. Carrington expects that Apple Pay will accelerate much of the growth of mobile payments at brick and mortar registers.

Net Element, Inc. (NASDAQ: NETE), a global payments-as-a-service, positions itself as a technology provider with an integrated mobile and transactional services platform serving emerging market clients. The company, through its subsidiary, TOT Group, Inc., operates Unified Payments that processes cashless transactions for card-present and non-present transactions, including point-of-sale, mobile point-of-sale, EMV, Apple Pay, near field communication, service based businesses, Internet businesses and mail order/telephone order merchants. NETE also operates Aptito, a cloud based software-as-a-service restaurant management solution, which offers integrated point-of-sale, mobile point of sale and various other functionality features to drive consumer engagement through Apple iPad-based point-of-sale, kiosk, and all other cloud-connected devices.

For more information on the company, visit www.netelement.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Energy Focus, Inc. (EFOI) Shining a Light on the Growing LED Lighting Industry

Energy Focus, Inc. (NASDAQ: EFOI) is a leading provider of energy efficient LED lighting products in the United States and abroad. The company’s current customer base includes national, state and local government agencies, Fortune 500 companies and a host of commercial and industrial clients. In addition, EFOI’s long-standing relationship with the U.S. government enables it to provide lighting products to the U.S. Navy and the Military Sealift Command fleets.

The global market for LED lighting products has expanded rapidly in recent years. According to a report by LEDs Magazine, increased demand is expected to drive a compound annual growth rate of 34 percent through 2016. As a result, the LED lighting marketing is expected to account for approximately $94 billion by 2020, representing nearly 60 percent of the total lighting market.

“The massive and lightning speed of LED lighting adoption… is indicative of what we could accomplish in the verticals we focus on expanding into such as military bases, hospitals and schools,” James Tu, executive chairman and chief executive officer of EFOI, stated in a news release.

In recent months, the company has made major strides toward capitalizing on this market growth. In the first quarter of 2015, EFOI recorded net sales of $13.1 million, realizing a 167 percent year-over-year increase. Additionally, the company’s income from operations improved by over $2 million, as compared to the first quarter of 2014.

“The first quarter of 2015 marked yet another exciting milestone from both operational and financial standpoints as we continued to grow at a rapid clip and were profitable from operations for the first time since our restructuring in the second half of 2013,” continued Tu. “Following improvements in our financial performance throughout 2014, we have now reported our fifth consecutive quarter of revenue growth led by strong shipments of our military Intellitube® for the U.S. Navy and continuing acceleration of our commercial product sales.”

On the commercial front, EFOI is in a strong position to continue building on the early success of its commercial Intellitube product, which was officially launched in April. This ‘one-tube-fits-all’ solution is a commercial version of the company’s proven military product, for which EFOI recently received an additional $6 million order from the U.S. Navy. By providing customers with the unique flexibility to either eliminate or postpone the upfront labor costs involved with removing existing ballasts, the commercial Intellitube is an innovative, economical option that could accelerate the adoption of LED tube lighting.

For prospective investors, the global shift toward LED lighting solutions makes EFOI an intriguing opportunity to realize sustainable returns moving forward. The company’s established presence in government and military markets and expanding impact on the commercial lighting industry should combine to drive continued financial growth in the months to come.

For more information, visit www.energyfocusinc.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Monday, June 22, 2015

ImmunoCellular Therapeutics, Ltd. (IMUC) Preparing to Address Underserved Market through Development of Leading Product Candidate

ImmunoCellular Therapeutics, Ltd. is a clinical stage biotechnology company developing immune-based therapies for the treatment of brain and other cancers. The company’s leading product candidate, ICT-107, is a vaccine that targets antigens associated with glioblastoma multiforme (GBM), the most common and lethal form of brain cancer. In recent weeks, ImmunoCellular has made progress toward the initiation of phase III clinical trials for the drug candidate, announcing an agreement with Caladrius Biosciences, Inc. for manufacturing services, including processing, packaging, labelling, quality control testing, release, shipping and storage. Building on this progress, patient enrollment for the trial is expected to begin by the early fourth quarter of this year.

When completed, ICT-107 will address a critically underserved market within the medical industry. According to a report by the American Cancer Society, an estimated 10,000 new patients are diagnosed with GBM in the United States each year. Despite advances in surgery, radiation and chemotherapy, recurrence is a near certainty and the median survival time for newly diagnosed GBM patients in only 14.6 months. In ImmunoCellular’s phase II trials for ICT-107, results suggested potential for greatly increased chances of long-term survival when treated with the company’s novel vaccine.

“We believe that we are on track to initiate the ICT-107 phase III trial in the late third quarter or fourth quarter of this year, following completion of the special protocol assessment process with the FDA and finalization of agreements with cancer cooperative groups and our contract research organization, which will manage the trial,” Andrew Gengos, chief executive officer of ImmunoCellular, stated in a news release. “We believe there is significant value in ImmunoCellular, given the breadth of our platforms and our preclinical and clinical assets, led by ICT-107.”

The company’s product pipeline also includes a dendritic cell-based vaccine that targets CD133, an antigen commonly associated with cancer stem cells. This candidate, known as ICT-121, is nearing the start of phase I clinical trials, with patient enrollment actively underway.

Moving forward, ImmunoCellular is in position to realize its corporate goal of becoming an industry-leading commercial-stage cancer immunotherapy company. Its pipeline of commercially attractive assets could provide the company with the opportunity to achieve sustainable returns while effectively transforming the treatment of cancer.

For more information, visit www.imuc.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html